Emerging Pharmacology — S42 and Next-Gen SARMs
Clinical research in 2026 has introduced more selective molecules designed to provide anabolic benefits without the systemic side effects of traditional steroids. A notable example is SARM S42, a structural analog of testosterone.
Tissue Specificity: Unlike older SARMs, S42 has shown the ability to increase muscle weight without stimulating prostate growth or causing significant acne.
Mechanism: It works by activating the mTORC1-p70S6K signaling pathway, which is essential for muscle protein synthesis, effectively mimicking the anabolic response of insulin.
1 vista